This is the authors' abstract. We don't add key points for this paper.
A series of [Ru(bipy)2L]+ and [Ru(phen)2L]+ complexes where L is 2-[5-(3,4-dimethoxyphenyl)-4H-1,2,4-triazol-3-yl]pyridine (HL1) and 4-(5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)benzene-1,2-diol (HL2) are reported. The compounds obtained have been characterised using X-ray crystallography, NMR, UV/Vis and emission spectroscopies. Partial deuteriation is used to determine the nature of the emitting state and to simplify the NMR spectra. The acid-base properties of the compounds are also investigated. The electronic structures of [Ru(bipy)2L1]+ and Ru(bipy)2HL1]2+ are examined using ZINDO. Electro and spectroelectrochemical studies on [Ru(bipy)2(L2)]+ suggest that proton transfer between the catechol and triazole moieties on L2 takes place upon oxidation of the L2 ligand.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: